Neuberg Diagnostics and Magnum Imaging inaugurates diagnostics centre in Trichy

Women Health Card was launched exclusively for women health workers of the Tiruchirappalli City Corporation

Hyderabad based CSIR institutes playing pivotal role in drug discovery and genetic diagnostics: Dr. Jitendra Singh

In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025

Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study

Morrisons introduces sensory support boxes in store for autistic and neurodiverse customers

Sensory Boxes include items such as drawing boards and fidget balls to support management of anxiety and improve shopping experience

GSK, UK Dementia Research Institute and Health Data Research UK to collaborate on first-of-its-kind dementia research initiative

The first-of-its-kind study will evaluate potential association between GSK’s shingles vaccine and reduced dementia risk, building on growing body of evidence from observational and retrospective studies

Cadila launches Cadilose for constipation and hepatic encephalopathy

Venus Remedies secures firstiInternational market authorization for Sugammadex from the Philippines

The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations

Roche Diagnostics India screens 5,000 children for eye health

Collaborates with VisionSpring to conduct eye check-up camps for underprivileged children

Sanofi updates on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

No safety signals related to the vaccine candidate were identified

Roche receives FDA approval for the first companion diagnostic to identify patients ultralow metastatic breast cancer

The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients.